Table 3.
Ergoespriometric responses during repeated all-out sprints (mean, upper row, ± SD, lower row).
| Sprint 1 | Sprint 2 | Sprint 3 | Sprint 4 | Sprint 5 | ANOVA effects | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| W1A | W1B | W1C | W2A | W2B | W2C | W60A | W60B | W60C | W15A | W15B | W15C | W15FA | W15FB | W15FC | Sprint | Sprint × sex | Treat | Treat × sex | Sprint × Treat | |
| Wpeak (W)b | 814.9 | 822.8 | 798.0 | 768.1 | 767.7 | 790.0 | 617.9 | 695.1* | 684.4* | 288.0 | 311.9 | 343.9*¶ | 385.3 | 421.0 | 430.4* | 0.001 | 0.578 | 0.001 | 0.728 | 0.001 |
| 185.8 | 207.7 | 202.1 | 194.2 | 167.2 | 204.4 | 172.6 | 207.4 | 167.0 | 113.3 | 106.1 | 111.2 | 135.0 | 142.0 | 125.3 | ||||||
| Wmean (W)b | 428.5 | 419.0 | 414.3 | 390.4 | 383.7 | 383.0 | 233.4 | 247.8* | 249.0* | 165.4 | 172.5 | 183.9*¶ | 201.3 | 207.7 | 209.5 | 0.001 | 0.698 | 0.005 | 0.285 | 0.001 |
| 101.3 | 98.8 | 98.3 | 94.5 | 92.1 | 89.6 | 62.4 | 66.9 | 58.5 | 65.6 | 53.2 | 53.8 | 62.5 | 51.7 | 50.4 | ||||||
| HR (beat.min−1) | 156.6 | 155.9 | 158.7 | 158.6 | 158.5 | 161.0 | 169.3 | 168.5 | 170.1 | 173.3 | 174.9 | 176.2 | 173.3 | 175.0 | 178.1 | 0.001 | 0.082 | 0.92 | 0.27 | 0.3 |
| 13.6 | 15.5 | 18.4 | 15.0 | 16.6 | 15.5 | 13.5 | 14.5 | 11.4 | 15.9 | 14.2 | 9.9 | 15.7 | 16.2 | 10.1 | ||||||
| VO2 (mL/min) | 1006.3 | 1011.8 | 1010.4 | 1065.7 | 1063.6 | 1057.9 | 2415.1 | 2426.2 | 2429.1 | 540.1 | 549.2 | 550.7 | 635.7 | 641.9 | 644.4 | 0.001 | 0.001 | 0.91 | 0.4 | 0.99 |
| 227.6 | 247.4 | 213.3 | 254.4 | 255.9 | 236.4 | 578.8 | 604.6 | 567.0 | 160.9 | 161.7 | 131.9 | 185.5 | 181.5 | 193.0 | ||||||
| VCO2 (mL/min) | 2012.5 | 2023.7 | 2020.8 | 2131.3 | 2127.3 | 2115.7 | 2415.1 | 2426.2 | 2429.1 | 2160.3 | 2197.0 | 2202.8 | 2542.8 | 2567.5 | 2577.5 | 0.001 | 0.18 | 0.88 | 0.4 | 0.98 |
| 455.2 | 494.7 | 426.7 | 508.8 | 511.7 | 472.9 | 578.8 | 604.6 | 567.0 | 643.7 | 646.7 | 527.7 | 741.9 | 725.8 | 772.2 | ||||||
| O2 deficit (mL) | 1611.5 | 1601.0 | 1605.5 | 1367.1 | 1378.4 | 1332.3 | 810.0 | 927.2 | 768.1 | 57.0 | 75.9 | 90.8* | 63.5 | 70.2 | 76.2 | 0.001 | 0.001 | 0.37 | 0.62 | 0.105 |
| 520.6 | 536.4 | 495.1 | 456.8 | 445.9 | 440.2 | 427.2 | 531.7 | 432.3 | 94.6 | 142.9 | 108.5 | 115.7 | 120.7 | 123.4 | ||||||
| RER | 1.02 | 1.04 | 1.02 | 1.03 | 1.04 | 1.03 | 0.97 | 0.98 | 0.96 | 1.16 | 1.18 | 1.16 | 1.04 | 1.05 | 1.07 | 0.001 | 0.012 | 0.574 | 0.61 | 0.62 |
| 0.11 | 0.11 | 0.11 | 0.08 | 0.07 | 0.09 | 0.07 | 0.07 | 0.05 | 0.09 | 0.08 | 0.07 | 0.08 | 0.06 | 0.12 | ||||||
| VE (L/min) | 78.2 | 79.2 | 76.9 | 98.9 | 99.6 | 98.0 | 112.2 | 113.2 | 111.6 | 118.8 | 121.9 | 117.1 | 121.1 | 122.5 | 123.3 | 0.001 | 0.027 | 0.84 | 0.67 | 0.98 |
| 22.5 | 22.1 | 23.1 | 23.7 | 25.7 | 28.0 | 29.4 | 30.3 | 30.5 | 35.0 | 33.4 | 37.0 | 36.7 | 35.3 | 36.8 | ||||||
| PETO2 (mmHg) | 115.5 | 114.6 | 112.6 | 119.7 | 119.7 | 119.3 | 119.8 | 120.1 | 120.0 | 122.6 | 122.9 | 119.5 | 119.9 | 119.9 | 120.5 | 0.001 | 0.34 | 0.21 | 0.633 | 0.405 |
| 5.3 | 4.6 | 11.9 | 3.2 | 3.1 | 4.7 | 2.9 | 2.6 | 2.8 | 2.6 | 2.4 | 17.1 | 2.4 | 2.5 | 2.7 | ||||||
| PETCO2 (mmHg) | 29.0 | 30.5 | 29.9 | 25.6 | 25.9 | 26.3 | 24.2 | 24.1 | 24.4 | 24.6 | 24.7 | 24.3 | 25.7 | 25.7 | 25.7 | 0.001 | 0.099 | 0.6 | 0.6 | 0.34 |
| 3.7 | 3.7 | 4.3 | 2.3 | 2.5 | 3.5 | 2.5 | 2.2 | 2.5 | 2.6 | 2.2 | 4.5 | 2.5 | 2.5 | 2.7 | ||||||
Wpeak, peak power output; Wmean, mean power output; HR, heart rate; VO2, oxygen uptake; VCO2, CO2 production; RER, respiratory exchange ratio; VE, pulmonary ventilation; PETO2, end-tidal O2 pressure; PETCO2, end-tidal CO2 pressure; W1, first Wingate (30 s sprint); W2, second Wingate (30 s sprint); W60, 60 s sprint; W15, 15 s sprint post-ischemia; W15F, final 15 s sprint; Treat, treatment effect. A, Placebo; B, luteolin + Mangiferin; C, Mangiferin + Quercetin + Tiger nut extract (bstatistical analysis done with logarithmically transformed data);
*
P < 0.05 compared with placebo;
¶
P < 0.05 compared with treatment B.